Processa Pharmaceuticals, Inc. PCSA
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 10.80% | -4.17% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -29.87% | -10.01% | |||
| Operating Income | 29.87% | 10.01% | |||
| Income Before Tax | 3.31% | -0.54% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 3.31% | -0.54% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 3.31% | -0.54% | |||
| EBIT | 29.87% | 10.01% | |||
| EBITDA | 29.87% | 10.01% | |||
| EPS Basic | 7.80% | 13.51% | |||
| Normalized Basic EPS | 7.79% | 13.51% | |||
| EPS Diluted | 7.80% | 13.51% | |||
| Normalized Diluted EPS | 7.79% | 13.51% | |||
| Average Basic Shares Outstanding | 4.86% | 16.25% | |||
| Average Diluted Shares Outstanding | 4.86% | 16.25% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||